Directorate Update and Grant of Options

04 Jun 2018

Alderley Park, 4 June 2018 Redx (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces that, further to the announcement made on 24 April 2018, Lisa Anson assumed her new role as Chief Executive Officer on 1 June 2018 and has become a member of Redx Pharma’s Board of Directors.  Iain Ross has reverted to the role of Non-Executive Chairman.

In addition the company announces that on 1 June 2018 options over 3,600,000 ordinary shares of 1p each in the share capital of the Company, were granted to Lisa Anson, Chief Executive Officer, on the following basis:

Granted 1,800,000 Options under Redx’s Enterprise Management Incentive Scheme. 

600,000 options are exercisable at a price of 13.75p and will vest immediately
600,000 options are exercisable at a price of 20p and will vest immediately
600,000 options are exercisable at a price of 27p and will vest on the 1-year anniversary of the grant,

Granted 1,800,000 Unapproved Options

600,000 options are exercisable at a price of 35p and will vest on the 1-year anniversary of the grant,
600,000 options are exercisable at a price of 42.5p p and will vest on the 2-year anniversary of the grant.
600,000 options are exercisable at a price of 50p and will vest on the 2-year anniversary of the grant.

None of these options will become exercisable until the second anniversary of grant. 

For further information, please contact:

Redx Pharma Plc 

T: +44 1625 469 918

Iain Ross, Executive Chairman

Cantor Fitzgerald Europe (Nominated Advisor & Broker)

 T: +44 20 7894 7000

Phil Davies

WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/ Chris Lee/ David Wilson

FTI Consulting

T: +44 20 3727 1000

Simon Conway/Stephanie Cuthbert

About Redx Pharma Plc 

Redx is a UK biotechnology Group whose shares are traded on AIM (AIM:REDX). Redx is focused on creating and developing first, or potentially best in class drugs, in specific areas of cancer and fibrosis that address significant unmet medical need. Redx has an in-house discovery team with proven world-class chemistry capabilities. 

If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts.

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Lisa Anson

2

Reason for notification

 

 

 

a.

Position/Status

Chief Executive Officer

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Redx Pharma Plc

b.

LEI

213800HMS4EBXO589Y37

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Options over Ordinary Shares of 1p each

 

ISIN: GB00BSNB6S51

b.

Nature of the transaction

Grant of options under the EMI Share Scheme

 

Grant of Unapproved Options

 

c.

Price(s) and volume(s)

Granted 1,800,000 Options under Redx’s Enterprise Management Incentive Scheme.

 

600,000 options are exercisable at a price of 13.75p and will vest immediately

600,000 options are exercisable at a price of 20p and will vest immediately

600,000 options are exercisable at a price of 27p and will vest on the 1-year anniversary of the grant,

 

 

 

Granted 1,800,000 Unapproved Options

 

600,000 options are exercisable at a price of 35p and will vest on the 1-year anniversary of the grant,

600,000 options are exercisable at a price of 42.5p p and will vest on the 2-year anniversary of the grant.

600,000 options are exercisable at a price of 50p and will vest on the 2-year anniversary of the grant.

 

d.

Aggregated information

– Aggregated Volume

– Price

N/A – Single Transaction

e.

Date of the transaction

01/06/18

f.

Place of the transaction

Outside of trading venue